Table 3:
Added value APOL1 risk genotype to polygenic risk components in predicting CKD using extreme tail (98th percentile) of the risk score distribution in African-American (4,268 cases and 10,276 controls) and admixed Latinx (1,386 cases and 2,239 controls) cohorts. All effect estimates are adjusted for age, sex, diabetes, and principal components of ancestry.
| Cohorts | APOL1 Risk Genotype OR (95%CI), P-value | Top 2% PRS without APOL1 OR (95%CI), P-value | Top 2% PRS with APOL1 OR (95%CI), P-value |
|---|---|---|---|
| African Ancestry: | |||
| eMERGE | 1.64 (1.42-1.86), P=2.00E-05 | 2.10 (1.46-2.74), P=2.00E-02 | 2.60 (1.38-4.90), P=3.10E-03 |
| BioMe | 1.38 (1.28-1.48), P=3.30E-10 | 2.70 (1.93-3.47), P=1.00E-02 | 5.75 (4.96-6.54), P=1.00E-05 |
| UAB HyperGen | 1.71 (0.93-3.12), P=8.20E-02 | 2.22 (0.59-8.44), P=2.40E-01 | 1.64 (0.43-6.20), P=4.65E-01 |
| UAB REGARDS | 1.35 (1.08-1.77), P=6.90E-03 | 1.26 (0.76-2.07), P=3.60E-01 | 1.56 (0.97-2.59), P=6.52E-02 |
| UAB GenHAT | 1.43 (1.12-1.81), P=3.20E-03 | 2.80 (1.64-4.77), P=1.50E-04 | 4.38 (2.56-7.50), P=6.80E-08 |
| UAB Warfarin | 1.93 (1.07-3.49), P=2.90E-02 | -- | 1.59 (0.28-8.73), P=5.96E-01 |
| Meta-analysis | 1.46 (1.38-1.54), P=2.70E-19 | 1.76 (1.41-2.20), P=5.90E-07 | 2.66 (2.01-3.51), P=4.93E-12 |
|
| |||
| Latinx Admixed Ancestry: | |||
| eMERGE | 16.5 (5.70-48.1), P=7.10E-04 | 1.41 (0.47-4.24), P=5.40E-01 | 6.89 (1.60-29.07), P=9.78E-03 |
| BioMe | 1.17 (1.10-1.24), P=2.40E-06 | 2.72 (1.97-3.47), P=1.00E-02 | 4.48 (3.69-5.27), P=2.10E-04 |
| Meta-analysis | 1.18 (1.09-1.27), P=4.40E-05 | 2.21 (1.19-4.10), P=1.10E-02 | 4.93 (2.46-9.89), P=6.69E-06 |